Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group Meeting Objective: To review recent AI-CVD and Agatston-2.0 research progress, discuss the latest LDCT Mega Trial / LIFEMAP study design, evaluate key unresolved protocol questions, introduce LUNGevity as a potential nonprofit administrative and advocacy partner, and begin discussion of funding sources and fundraising plans. 1. Opening Remarks Dr. Mo

Campaign contrasts coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach: one lower-cost, lower-radiation, non-contrast CT scan, 10+ actionable reports, and broader cardiovascular and cardiometabolic risk phenotyping. SAN DIEGO, July 6, 2026 - HeartLung Corporation (HeartLung.AI), a medical AI company transforming CT imaging into preventive care intelligence, today announced the launch of its "Why Pay More and Get Less?"

AI-derived left atrial volume and chamber ratios from CAC scans predicted long-term AF and stroke in MESA and Framingham. HOUSTON, June 18, 2026 - HeartLung.AI today announced that its research article, "AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke," was featured on the June 2026 episode of the Stroke Alert Podcast, the podcast of Stroke, a journal of the American Heart Associatio

New peer-reviewed study introduces Agatston-2.0, led by Morteza Naghavi, MD, with Arthur S. Agatston, MD, the originator of the original Agatston score, and leading cardiovascular imaging and prevention experts. HOUSTON, TX, June 2026 — HeartLung Corporation today announced the publication of a landmark peer-reviewed study introducing Agatston-2.0, a next-generation artificial intelligence-based coronary artery calcium scoring method designed to modernize one of the most infl

HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,

Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology

New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary inflammation assessment HOUSTON, TX, UNITED STATES, May 3, 2026 /EINPresswire.com/ -- HeartLung Corporation, a medical technology company advancing AI–enabled, CT–based opportunistic screening and early disease detection, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,620,494, titled “Predicting adverse healt

CMS Code G0680 opens doors to AI-enabled opportunistic detection of patients with silent coronary artery disease who are unaware of their risk of a future heart attack. HOUSTON, April 7, 2026 -- HeartLung AI today welcomed CMS’s establishment of HCPCS code G0680 in the April 2026 Hospital Outpatient Prospective Payment System update, effective April 1, 2026, for algorithmic analysis of coronary artery calcium (CAC) and/or aortic valve calcification from chest CT with report.